Detalhe da pesquisa
1.
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
JAMA
; 330(6): 512-527, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459141
2.
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials.
Alzheimers Dement
; 19(12): 5407-5417, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37204338
3.
Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
JAMA
; 330(23): 2304-2305, 2023 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38112817
4.
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(3): e12415, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37600216
5.
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
JAMA Neurol
; 79(10): 1015-1024, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36094645